OnCo

Stay in the loop

Leave your email and OnCo will write when something big changes in cancer research. No spam, one click to unsubscribe.

Email updates open shortly. Until then, press Watch on any page to keep it on your list.

trialsTrialRecruiting

A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors

A phase 1/2 trial of FMC-376 in non-small-cell lung cancer, colorectal cancer and pancreatic ductal adenocarcinoma, run by Frontier Medicines Corporation, now recruiting.